Normal Curves: Sexy Science, Serious Statistics
Normal Curves: Sexy Science, Serious Statistics
Podcast Description
Normal Curves is a podcast about sexy science & serious statistics. Ever try to make sense of a scientific study and the numbers behind it? Listen in to a lively conversation between two stats-savvy friends who break it all down with humor and clarity. Professors Regina Nuzzo of Gallaudet University and Kristin Sainani of Stanford University discuss academic papers journal club-style — except with more fun, less jargon, and some irreverent, PG-13 content sprinkled in. Join Kristin and Regina as they dissect the data, challenge the claims, and arm you with tools to assess scientific studies on your own.
Podcast Insights
Content Themes
The podcast centers around the intersection of science and statistics, delving into topics such as the interpretation of scientific studies, statistical methodologies, and the implications of research findings, with episode examples including critiques of recent medical studies and discussions on how to understand p-values and confidence intervals.

Normal Curves is a podcast about sexy science & serious statistics. Ever try to make sense of a scientific study and the numbers behind it? Listen in to a lively conversation between two stats-savvy friends who break it all down with humor and clarity. Professors Regina Nuzzo of Gallaudet University and Kristin Sainani of Stanford University discuss academic papers journal club-style — except with more fun, less jargon, and some irreverent, PG-13 content sprinkled in. Join Kristin and Regina as they dissect the data, challenge the claims, and arm you with tools to assess scientific studies on your own.
Could a new gene therapy slow the progression of Huntington’s disease? Early results suggested an astonishing 80% reduction in disease progression. But there’s a catch: the evidence comes from just a handful of treated patients, compared with patients from an entirely different study. How can we know whether we’re comparing like with like? We dig into the science behind the treatment, the statistical challenges of finding a fair comparison group, and the heated controversy between the drug company and the FDA. Along the way, we take a statistical detour into propensity score matching—and wrestle with a difficult question: How much evidence should we demand when patients are running out of time?
Statistical topics
- External control groups
- Randomized controlled trials
- Sham surgery controls
- Propensity scores
- Restricted full propensity score matching
- Inverse probability of treatment weighting (IPTW)
- Confounding
- Selection bias
Methodologic Morals
- “Seventeen patients is still 17 patients, no matter how you cut it and no matter how many controls you have.”
- “With external controls, the question is always, are we seeing the treatment or are we seeing the difference between the studies?”
References
- uniQure. uniQure announces update on US Phase I/II clinical trial of AMT-130 gene therapy for the treatment of Huntington’s disease. June 21, 2023.
- uniQure. uniQure announces positive interim data update demonstrating slowing of disease progression in Phase I/II trials of AMT-130 for Huntington’s disease. July 9, 2024.
- uniQure. uniQure announces positive topline results from pivotal Phase I/II study of AMT-130 in patients with Huntington’s disease. September 24, 2025.
- uniQure. Pivotal Phase I/II AMT-130 program update: 36-month analysis. Investor presentation. September 24, 2025.
- uniQure announces additional data from ongoing Phase I/II studies of AMT-130 in Huntington’s disease showing continued slowing of disease progression. September 29, 2026.
- uniQure. Investor presentations and archived webcasts.
- uniQure. uniQure announces alignment with FDA on key elements of accelerated approval pathway for AMT-130 in Huntington’s disease. December 10, 2024.
- uniQure. uniQure provides regulatory update on AMT-130 for Huntington’s disease. November 3, 2025.
- uniQure. uniQure provides regulatory update on AMT-130 for Huntington’s disease. March 2, 2026.
- uniQure. uniQure announces plan for BLA submission for AMT-130 in Huntington’s disease. June 17, 2026.
- uniQure. uniQure announces FDA acceptance and priority review of the Biologics License Application for ifezuntirgene inilparvovec for the treatment of Huntington’s disease. November 2, 2026.
- Feuerstein A. FDA is ‘not convinced’ UniQure’s Huntington’s therapy has benefit, senior official says. STAT. March 3, 2026.
- Reuters. Senior FDA official calls uniQure’s Huntington’s disease treatment a failure. March 5, 2026.
- Jewett C. F.D.A. faces upset over denials of new drugs. New York Times. March 5, 2026.
- Jackson K. Bring hope to Huntington’s disease families: Urge the FDA to uphold accelerated approval. Change.org.
Kristin and Regina’s online courses:
Demystifying Data: A Modern Approach to Statistical Understanding
Clinical Trials: Design, Strategy, and Analysis
Medical Statistics Certificate Program
Epidemiology and Clinical Research Graduate Certificate Program
Program that Kristin teaches in::
Epidemiology and Clinical Research Graduate Certificate Program
Kristin’s manuscript writing course:
https://instats.org/seminar/from-data-to-discussion-writing-a-scient
Find us on:
Kristin – LinkedIn & Twitter/X
Regina – LinkedIn &ReginaNuzzo.com
- (00:00) – Cold Open: FDA Demands a Bigger Trial
- (08:17) – Huntington’s Genetics: Dominant Inheritance and CAG Repeats
- (18:05) – AMT-130: Gene Therapy Delivered by Brain Surgery
- (20:31) – Early Trials, Sham Surgery, and Safety
- (26:55) – External Controls: A Statistical Detour
- (30:04) – Two-Year Headline: 80% Reduction
- (37:39) – Propensity Scores: Barbie vs. Oppenheimer
- (50:11) – FD…

Disclaimer
This podcast’s information is provided for general reference and was obtained from publicly accessible sources. The Podcast Collaborative neither produces nor verifies the content, accuracy, or suitability of this podcast. Views and opinions belong solely to the podcast creators and guests.
For a complete disclaimer, please see our Full Disclaimer on the archive page. The Podcast Collaborative bears no responsibility for the podcast’s themes, language, or overall content. Listener discretion is advised. Read our Terms of Use and Privacy Policy for more details.